A Phase 1/2 open-label study in Parkinson’s disease reported first human outcomes for STEM-PD, transplanting cryopreserved, off-the-shelf dopamine progenitor cells derived from human pluripotent stem cells. The trial enrolled eight participants at Lund University and Skåne University Hospital, and published results in Nature Medicine described no serious side effects linked to the transplanted cells during the first year of follow-up. The STEM-PD program targets the dopamine neuron loss that drives Parkinson’s motor symptoms, with the intended mechanism to restore dopaminergic circuitry. The study’s authors framed feasibility and safety as key stepping stones toward broader patient cohorts. Industry watchpoints for cell therapies include tumorigenicity risk management, graft integration, and functional endpoint durability. While longer follow-up will be needed, the early data support ongoing clinical development toward larger efficacy-focused trials. The milestone also highlights how regional academic centers are advancing stem-cell Parkinson’s programs with an emphasis on standardized starting materials and scalable manufacturing approaches.